Hypothesis formulation from subgroup analyses: Nonadherence or nonsteroidal anti-inflammatory drug use explains the lack of clinical benefit of aspirin on first myocardial infarction attributed to "aspirin resistance"

American Heart Journal

Volumn 159, Issue 5, 2010, Pages 744-748

  Hennekens, Charles H ^a,b   Schneider, Wendy R ^a,b   Hebert, Patricia R ^a,b   Tantry, Udaya S ^c   Gurbel, Paul A ^c,d  

^a FLORIDA ATLANTIC UNIVERSITY   (United States)

^b NOVA SOUTHEASTERN UNIVERSITY   (United States)

^c SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

AGE; ARTICLE; ASPIRIN RESISTANCE; BODY MASS; CLINICAL TRIAL; DRUG RESISTANCE; EXERCISE; HEART INFARCTION; HUMAN; HYPERTENSION; PATIENT COMPLIANCE; PRIMARY PREVENTION; PRIORITY JOURNAL; SMOKING;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; DRUG TOLERANCE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT COMPLIANCE; PROPORTIONAL HAZARDS MODELS;

EID: 77951617363     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2009.11.033     Document Type: Article

References (18)

1. Michelson A.D., Cattaneo M., Eikelboom J.W., et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 3 (2005) 1309-1311
2. Hankey G.J., and Eikelboom J.W. Aspirin resistance. Lancet 367 (2006) 606-617
3. Hennekens C.H., Schror K., Weisman S., et al. Terms and conditions: semantic complexity and aspirin resistance. Circulation 110 (2004) 1706-1708
4. Patrono C., García Rodríguez L.A., Landolfi R., et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353 (2005) 2373-2383
5. Santilli F., Rocca B., De Cristofaro R., et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays implications for aspirin "resistance". J Am Coll Cardiol 53 (2009) 667-677
6. Catella-Lawson F., Reilly M.P., Kapoor S.C., et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345 (2001) 1809-1817
7. MacDonald T.M., and Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 361 (2003) 573-574
8. Kurth T., Glynn R.J., Walker A.M., et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 108 (2003) 1191-1195
9. Eikelboom J.W., Hirsh J., Weitz J.I., et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105 (2002) 1650-1655
10. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 321 (1989) 129-135
11. Glynn R.J., Buring J.E., Manson J.E., et al. Adherence to aspirin in the prevention of myocardial infarction. The Physicians' Health Study. Arch Intern Med 154 (1994) 2649-2657
12. Gum P.A., Kottke-Marchant K., Welsh P.A., et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41 (2003) 961-965
13. Chen W.H., Lee P.Y., Ng W., et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 43 (2004) 1122-1126
14. Lev E.I., Patel R.T., Maresh K.J., et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 47 (2006) 27-33
15. Gurbel P.A., Bliden K.P., DiChiara J., et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 115 (2007) 3156-3164
16. Lordkipanidzé M., Pharand C., Schampaert E., et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 28 (2007) 1702-1708
17. Eikelboom J.W., Hankey G.J., Thom J., et al. Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Investigators. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation 118 (2008) 1705-1712
18. Tantry U.S., Bliden K.P., and Gurbel P.A. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 46 (2005) 1705-1709